XEIA Venture Partners

XEIA Venture Partners is an active venture capital firm investing in early-stage companies at the intersection of life sciences, AI, hardware/software, deep tech and health tech. Their portfolio spans companies advancing health and human performance through novel technologies[1][8][9].

The fund was established in 2021 and has recently launched its second fund as of April 2025[3][2]. They are based in San Francisco with additional presence noted in Los Angeles[2][4]. Key people include Founding Partner Brom Rector and Partner Sam Tabone[9].

While they invest heavily in life sciences and healthcare innovation—including biotechnology—they do not themselves develop drugs or therapeutic platforms.

Their investment focus includes but may not be limited to biotech startups working on new modalities or indications; however specific pipeline programs are those of their portfolio companies rather than the fund itself.